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Multiple Myeloma
The effect of zoledronic acid on serum
osteoprotegerin in early stage multiple myeloma
We evaluated the effect of zoledronic acid (ZA)
on serum levels of osteoprotegerin (OPG) and the
ligand for receptor activator of nuclear factor κB
(RANKL) in patients with smoldering myeloma. In
treated subjects we found an increase of OPG
accounting for an effect of ZA on osteoblast and/or




Multiple myeloma (MM) is characterized by the pres-
ence of lytic bone lesions, reflecting an increase in osteo-
clastic bone resorption.1 The ligand for receptor activator
of nuclear factor-κB (RANKL) has been identified and
associated with the increase in osteoclast-induced bone
resorption in MM. By contrast, osteoprotegerin (OPG)
acts as a soluble neutralizing receptor for RANKL and
inhibits osteoclast formation.2-3 Several data have demon-
strated that myeloma cells are able to induce an imbal-
ance in the OPG/RANKL system in bone environment.4
Bisphosphonates are potent inhibitors of osteoclast activ-
ity and bone resorption. However, it has been recently
demonstrated that bisphosphonate treatment can
increase OPG production both in vitro from primary
human osteoblasts and in vivo in patients with Paget’s dis-
ease of bone.5-6 A recent study in 43 MM patients with
stage IA diseases showed that prophylactic administra-
tion of the bisphosphonate pamidronate does not
improve overall progression-free survival but could limit
the development of bone disease, expressed as skeletal
related events (SRE), at progression.7
The aims of our study were to evaluate whether the
inhibition of osteoclast activity in smoldering MM,
obtained with  the potent aminobisphosphonate zole-
dronic acid (ZA) without other pharmacological interfer-
ence, can be related to changes in circulating levels of
RANKL and OPG.   
Twenty-six consecutive patients (14 males/12 females;
median age 71.4±7.8, range 49-82 years) with smoldering
MM (14  IgG/κ, 2 IgG/λ, 8 IgA/κ, 2 IgA/λ) were recruited
between October 2004 and March 2005 from the
Department of Hematology of the University of Siena.
Fifty-eight healthy age- and sex-matched subjects were
used as controls. After baseline evaluation, the patients
with smoldering MM were randomly assigned to receive
no treatment (10 patients) or ZA (16 patients), 4 mg
administered as a 15 min infusion at baseline and at
months 1, 2, 4 and 6. 
Basal biochemical and densitometric data of the
patients and controls are shown in Table 1. Basal OPG
levels were significantly lower in patients with smolder-
ing MM than in controls. An increase of the
RANKL/OPG ratio, an expression of osteoclast activity,
was also observed. Biochemical variations at different
times in treated and untreated patients are shown in
Table 2. As expected, an early and significant reduction of
serum  C-terminal telopeptides (CTX) was found in treat-
ed patients, while bone alkaline phosphatase decreased
later but not significantly.8 The significant correlation
between RANKL/OPG ratio and serum of type-1 collagen
(CTX) (r=0.45; p<0.05) confirmed the influence of the
RANKL/OPG system on osteoclast activity. Remarkably,
ZA caused a progressive and significant increase of serum
OPG while serum RANKL resulted unchanged. The
decrease of the RANKL/OPG ratio in treated patients was
not significant. The positive effect of ZA on bone tissue
was confirmed by an increased bone mineral density of
the lumbar spine at 6 months (+3.8%±2.6 vs baseline;
p<0.05). Moreover, we did not observe significant differ-
ences in monoclonal protein variations in treated or
untreated patients and no disease progression.
In this study ZA administration was found to modify
the biochemical abnormalities occurring in smoldering
MM, characterized at baseline by low levels of serum
OPG and increased RANKL/OPG ratio. To our knowl-
edge, this is the first time that an in vivo increase of serum
OPG after ZA administration in MM has been demon-
strated. Our data are in keeping with in vitro observations
showing that ZA both stimulates OPG production and
inhibits RANKL as well as myeloma cell growth.5 These
data could be the biochemical explanation for the poten-
tial benefit of ZA treatment in early stage asymptomatic
myeloma patients. 
In fact the reduction of SRE in patients with smolder-
ing MM treated with pamidronate in the study  by Musto
et al. could potentially be explained by these changes in
RANKL/OPG balance.9 There are questions about
whether the increase in OPG is correlated with disease
progression. RANKL/OPG ratio showed a not significant
decrease after the first month from the beginning of ther-
apy, as did serum RANKL. There are, however, major
concerns about the interpretation of serum RANKL lev-
els. In fact RANKL is produced by both osteoblasts and T-
cells and these cells can express a cell-specific membrane-
bound RANKL that is cleaved by metalloproteinase in a
soluble form. 
There may be some functional differences between
membrane-bound and soluble RANKL, with the cell-
bound form being more effective mediators of osteoclas-
togenesis when measured by in vitro assays. Available
Table 1. Biochemical characteristics of patients at baseline and
controls.
Smoldering myeloma Controls Significance
n=26 n=58
Calcium (mg/dL) 9.2±0.4 9.3±0.5 ns
Phosphorus (mg/dL) 3.3±0.5 4.0±0.7 p<0.01
Creatinine (mg/dL) 1.0±0.2 0.8±0.3 p<0.01
UCalcium (mg/24h) 140±60 135±58 ns
Bone ALP (U/L) 10.9±4 12.1±5 ns
CTX (ng/mL) 0.46±0.20 0.39 ± 0.17 ns
MIP-1α (pg/mL) 25.3±13 22.5±10 ns
OPG (pmol/L) 2.8±1.7 9.2±6.1 p<0.01
RANKL (pmol/L) 0.27±0.18 0.28±0.23 ns
RANKL:OPG 0.20±0.39 0.06±0.11 p<0.05
LSpineBMD (g/cm2) 1.07±0.24 0.862±0.16 p<0.01
T-score LSpine -0.26±1.95 -2.21±1.44 p< 0.01
FNeck BMD (g/cm2) 0.84±0.16 0.724±0.09 p<0.01
T-score Fneck -1.29±1.09 -1.93±0.82 p<0.01
THip BMD (g/cm2) 0.93±0.16 0.829±0.10 p<0.01 
T-score THip -0.87±1.13 -1.45±0.80 p<0.01
UCalcium: urinary calcium; Bone ALP: bone alkaline phosphatase; CTX: C-ter-
minal telopeptides of Type-I collagen; MIP: macrophage inflammatory protein;
OPG: osteoprotegerin;  BMD: bone mineral density; LSpine: lumbar spine;
FNeck: femoral neck; THip: total hip. T-score is the difference in standard
deviation from the mean value in healthy young people. 
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ELISA assays measure only the soluble form and this
could explain the lack of statistical significance of our
results. In conclusion, the most important finding of this
study is that the administration of ZA without other
pharmacological treatment is able to increase the serum
level of OPG in patients with smoldering MM. 
Giuseppe Martini,* Alessandro Gozzetti,° Luigi Gennari,*
Annalisa Avanzati,* Ranuccio Nuti,* Francesco Lauria°
*Department of Internal Medicine, University of Siena, Siena,
Italy; °Division of Hematology and Transplants,
University of Siena,  Siena, Italy
Key words: multiple myeloma, osteoprotegerin, zoledronic acid,
RANKL.  
Correspondence: Giuseppe Martini,  Policlinico “Santa Maria
Le Scotte” 53100 Siena, Italy. Phone: international
+39.057.7586453. E-mail: martinig@unisi.it
References
1. Roodman GD. Biology of osteoclast activation in cancer. J Clin
Oncol 2001;19:2892-8.
2. Lacey DL, Timms E, Tan HL,  Kelley MJ, Dunstan CR, Burgess
T, et al. Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell 1998;93:165–76.
3. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C,
et al. OPGL is a key regulator of osteoclastogenesis, lympho-
cyte development and lymph-node organogenesis. Nature
1999; 397:315–23.
4. Giuliani N, Bataille R, Mancini C Lazzaretti M, Barille S.
Myeloma cells induce imbalance in the osteoprotegerin/osteo-
protegerin ligand system in the human bone marrow environ-
ment. Blood 2001;98: 3527-33.
5. Viereck V, Emons G, Lauck KH, Frosch KH, Blaschke S, Grund -
ker C, et al. Bisphosphonates pamidronate and zoledronic acid
stimulate osteoprotegerin production by primaryhuman
osteoblasts  Biochem Biophys Res Commun 2002; 291:680-6.
6. Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB,
Campagna S, et al. Serum OPG and RANKL levels before and
after intravenous bisphosphonate treatment in Paget’s disease
of bone. Bone[Epub ahead of print].  
7. Musto P,  Falcone A, Sanpaolo G, Bodenizza C, Carella AM.
Pamidronate in early-stage untreated myeloma. J Clin Oncol
2003; 16:3177-8. 
8. Terpos E, Politou M, Rahemtulla A. The role of markers of
bone remodelling in multiple myeloma Blood Rev 2005;19:
125-42.
9. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N,
Melillo L, et al. Pamidronate reduces skeletal events but does
not improve progression-free survival in early-stage untreated
myeloma: results of a randomized trial. Leuk Lymphoma
2003;44:1545–8.
Table 2. Biochemical variations at different times iin patients treated or not treated with zoledronic acid.
Baseline 1 Months 3 Months 6 Months
Treated Untreated Treated Untreated Treated Untreated Treated Untreated
n=16 n=10 n=16 n=10 n=16 n=10 n=16 n=10
Calcium (mg/dL) 9,2±0,4 9,0±0,2 9,0±0,8 8,9±0,3 8,9±0,7 9,0±0,4 9,0±0,7 9,0±0,4
UCalcium (mg/24h) 137±77 157±78 99±67 135±41 112±76 157±75 138±74 161±96
Creatinine (mg/dL) 1,00±0,2 1,02±0,1 0,9±02 0,92±0,1 0,9±02 0,9±0,2 0,9±0,2 0,9±0,1
Bone ALP (U/L) 11,3±3,3 10,7±2,3 11,4±4,2 10,5±2,6 9,6±3,4 9,8±2,5 8,6±2,5 10,2±2,5
CTX (ng/m) 0,47±0,22* 0,38±0,1 0,22±0,07 0,48±0,12§ 0,29±0,18 0,48±0,13§ 0,26±0,12 0,52±0,12§ 
MPI-1α (pg/mL) 25,3±1,5 25,4±0,8 25,2±0,8 25,6±0,8 25,3±0,7 25,0±0,6 26,9±1,1 26,2±1,4
OPG (pmol/L) 2,55±1,8* 3,0±1,2 4,0±2,4 3,0±1,1 4,8±2,6 2,9±0,8§ 5,4±2,6 3,0±0,4§ 
RANKL (pmol/L) 0,26±0,19 0,28±0,14 0,27±0,17 0,30±0,13 0,25±0,16 0,28±0,12 0,28±0,16 0,32±0,11
RANKL/OPG 0,23±0,44 0,14±0,22 0,09±0,07 0,13±0,1 0,07±0,05 0,11±0,11 0,08±0,10 0,11±0,09
*p<0.05 treatment effect (repeated measures ANOVA); §p<0.05 untreated vs. treated (T-test for independent data). UCalcium: urinary calcium; Bone ALP: bone
alkaline phosphatase; CTX: C-terminal telopeptides of type-I collagen; MIP-1α: macrophage inflammatory protein-1α; OPG: osteoprotegerin.
